Current Surgical Indications for Non-Small-Cell Lung Cancer

Area of Science:

• Thoracic Oncology
• Surgical Oncology
• Medical Oncology

Background:

• Non-small cell lung cancer (NSCLC) management is rapidly advancing.
• Multimodality therapy requires careful patient selection and timing for optimal benefit.
• Surgery is a cornerstone of NSCLC treatment across various stages, including selected metastatic cases.

Purpose of the Study:

• To review current indications for surgical therapy in NSCLC stages I-IV.
• To discuss the impact of recent advances like immunotherapy and targeted therapy.
• To explore future directions in multidisciplinary lung cancer treatment.

Main Methods:

• Review of current literature and clinical trial data.
• Analysis of standard of care indications for surgical intervention.
• Discussion of emerging systemic therapies and biomarkers.

Main Results:

• Immunotherapy and targeted therapies represent significant advances in NSCLC treatment.
• These systemic therapies are expanding indications into earlier, surgically operable NSCLC.
• Multidisciplinary approaches, including surgery, are vital even in earlier disease stages.

Conclusions:

• Surgical therapy remains integral to NSCLC management, from early to selected advanced stages.
• Integration of novel systemic therapies with surgery is improving survival outcomes.
• Future lung cancer treatment will increasingly rely on multidisciplinary, personalized approaches.